Mainz Biomed N.V. announced that its non-invasive colorectal cancer (CRC) screening test, ColoAlert®, has received official registration and approval for distribution by Swissmedic, the Swiss regulatory and supervisory authority. This follows the company's partnership with labor team w ag earlier this year.
With this regulatory milestone, ColoAlert is now authorized for use in the Swiss market and will be made available through labor team w ag’s diagnostic service offering. The Swiss population in the 50 to 74 age group, the primary target for CRC screening, is estimated at approximately 2.8 million.
The introduction of ColoAlert in Switzerland aims to significantly improve participation rates in CRC screening programs, which currently fall below 50%. This approval supports Mainz Biomed’s broader strategy to expand access to reliable CRC screening solutions for early detection and to decrease related mortality rates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.